KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Gains from Sales and Divestitures (2021 - 2025)

LifeMD's Gains from Sales and Divestitures history spans 5 years, with the latest figure at $200000.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 86.25% year-over-year to $200000.0; the TTM value through Dec 2025 reached $200000.0, down 86.25%, while the annual FY2025 figure was $200000.0, 86.25% down from the prior year.
  • Gains from Sales and Divestitures reached $200000.0 in Q4 2025 per LFMD's latest filing, roughly flat from $200000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.5 million in Q4 2024 to a low of $26875.0 in Q2 2021.
  • Average Gains from Sales and Divestitures over 5 years is $340810.9, with a median of $120375.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 571.44% in 2024, then tumbled 90.97% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $77875.0 in 2021, then skyrocketed by 127.45% to $177125.0 in 2022, then skyrocketed by 280.88% to $674625.0 in 2023, then skyrocketed by 115.56% to $1.5 million in 2024, then crashed by 86.25% to $200000.0 in 2025.
  • Per Business Quant, the three most recent readings for LFMD's Gains from Sales and Divestitures are $200000.0 (Q4 2025), $200000.0 (Q3 2025), and $100000.0 (Q2 2025).